25 June 2012

Biotech does not spare money for research

In 2011, R&D expenses of biotech companies increased by 9%

Weekly Pharmacy www.apteka.ua according to Bloomberg materialsAccording to the data of the analytical company Ernst&Young, the R&D expenses of biotech companies led by Amgen Inc. and Celgene Corp. are characterized by positive growth indicators for the second year in a row.

Recall that in 2009, there was a reduction in R&D spending. Thus, the global volume of expenditures of biotech companies in 2009 decreased by 21%, which was the result of the economic crisis. At the same time, in 2011, the growth of investments in the R&D sector increased by 9% compared to 2010. The growth in R&D spending in 2010 amounted to 2% compared to the previous year. In 2011, 62% of joint-stock biotech companies in the United States increased spending on R&D.

At the same time, according to the results of 2011, the volume of sales of biotech companies increased by 10% compared to 2010. Thus, in 2011, sales revenue reached $33.4 billion. The USA is the largest indicator since 2000 . Total profit in this area decreased by 5% compared to 2010.

Over the past 5 years, investments of pharmaceutical companies in biotechnology through acquisitions or the conclusion of cooperation agreements have decreased by 30%. At the same time, the number of acquisitions of biotech companies increased from 49 in 2010 to 57 in 2011. However, only in 7 of the above cases, large pharmaceutical companies were buyers.

In 2011, 3 leading biotech companies with sales exceeding $500 million per year were acquired. Thus, Sanofi completed the acquisition of the biotech company Genzyme Corp. for $20.1 billion, and Teva Pharmaceutical Industries Ltd. – Cephalon Inc. for $6.2 billion. Talecris Biotherapeutics Holding Corp. was bought by the Spanish Grifols SA for $ 3 billion.

Portal "Eternal youth" http://vechnayamolodost.ru25.06.2012

Found a typo? Select it and press ctrl + enter Print version